Search research articles
Contact Us
Filters
Showing results (171-180 of 213) with videos related to
Page
of 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
Howard I Scher, Susan Halabi, Ian Tannock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, et al.
Journal of Midwifery & Women'S Health
|
November 9, 2024
Perinatal Loneliness and Isolation Early in the COVID-19 Pandemic in New York City: A Qualitative Study
Brooke S West, Lida Ehteshami, Clare McCormack, et al.
JCO Precision Oncology
|
May 29, 2020
<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Emmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, et al.
Cancer Medicine
|
November 11, 2024
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis
Motohide Uemura, Hiroaki Kikukawa, Yasuhiro Hashimoto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial
Joaquin Mateo, Johann S de Bono, Karim Fizazi, et al.
Cancer
|
May 8, 2014
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma
Maha Hussain, Stephanie Daignault, Neeraj Agarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2015
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer
Evan Y Yu, Hongli Li, Celestia S Higano, et al.
Chemical Senses
|
April 21, 2025
Prevalence of Olfactory Dysfunction among Postpartum Women and Impact of SARS-CoV-2 Infection During Pregnancy
Patricia T Jacobson, Elena Arduin, Maha Hussain, et al.
Journal of Patient-Reported Outcomes
|
June 29, 2018
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
Joseph M Unger, Katherine Griffin, Gary W Donaldson, et al.
Page
of 22
Search research articles
Search
Showing results (171-180 of 213) with videos related to
Sort By:
Page
of 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
Howard I Scher, Susan Halabi, Ian Tannock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, et al.
Journal of Midwifery & Women'S Health
|
November 9, 2024
Perinatal Loneliness and Isolation Early in the COVID-19 Pandemic in New York City: A Qualitative Study
Brooke S West, Lida Ehteshami, Clare McCormack, et al.
JCO Precision Oncology
|
May 29, 2020
<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Emmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, et al.
Cancer Medicine
|
November 11, 2024
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis
Motohide Uemura, Hiroaki Kikukawa, Yasuhiro Hashimoto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial
Joaquin Mateo, Johann S de Bono, Karim Fizazi, et al.
Cancer
|
May 8, 2014
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma
Maha Hussain, Stephanie Daignault, Neeraj Agarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2015
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer
Evan Y Yu, Hongli Li, Celestia S Higano, et al.
Chemical Senses
|
April 21, 2025
Prevalence of Olfactory Dysfunction among Postpartum Women and Impact of SARS-CoV-2 Infection During Pregnancy
Patricia T Jacobson, Elena Arduin, Maha Hussain, et al.
Journal of Patient-Reported Outcomes
|
June 29, 2018
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
Joseph M Unger, Katherine Griffin, Gary W Donaldson, et al.
Page
of 22